camptothecin has been researched along with Cystitis in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bilusic, M; Chau, CH; Cordes, LM; Dahut, WL; Figg, WD; Gulley, JL; Huitema, ADR; Karzai, F; Madan, RA; Peer, CJ; Schellens, JHM; Schmidt, KT; Wroblewski, S | 1 |
| de Vries, EG; Dumez, H; Gietema, JA; Groen, HJ; Maring, JG; Porro, M; van Oosterom, AT; Wachters, FM | 1 |
| Cohen, MH; Creaven, PJ; Hansen, HH; Muggia, FM; Selawry, OS | 1 |
2 trial(s) available for camptothecin and Cystitis
| Article | Year |
|---|---|
A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide.
Topics: Camptothecin; Cyclodextrins; Cystitis; Humans; Male; Nanoparticles; Nitriles; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome | 2022 |
A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours.
Topics: Adult; Antineoplastic Agents, Phytogenic; Camptothecin; Cystitis; Drug Administration Schedule; Drug Delivery Systems; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Polyvinyls | 2004 |
1 other study(ies) available for camptothecin and Cystitis
| Article | Year |
|---|---|
Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.
Topics: Camptothecin; Cystitis; Humans; Leukocyte Count; Leukopenia; Neoplasms; Thrombocytopenia | 1972 |